| » Home » Contact Us » Site Map | Register | Login |
Home
Welcome to NeuroPAS
| Chronic pain is a vexing problem for clinicians, patients, and society. Doctors are repeatedly frustrated when they feel they have found the source or sources of the specific patient’s pain symptoms only to have the patient fail treatment. The United States annual direct cost of pain treatment exceeds $100 billion. The impact of productivity and other costs are estimated at $350 billion annually. Current diagnostic tests do not correlate with patient symptoms. For example, in most cases of lumbar pain, imaging tests [x-rays, CT scans, MRI scans, etc] and neurologic tests [Nerve conduction studies, evoked potentials] do not correlate with the absence or presence of pain, the severity of pain, and treatment outcomes. Thus, these tests provide no definitive information about the source and severity of physical tenderness in many common conditions. |
|
| An accurate assessment of pain symptoms would improve treatment and reduce suffering and disability. Much of the above problem is due to the complexity of pain and the ambiguity inherent in making correct diagnoses. Sometimes clinicians fail to consider psychological and social issues that dominant the patient’s presentation [depression, anxiety, malingering, drug seeking]. Sometimes clinicians incorrectly blame the pain on the wrong tissue pain generator [arthritis when the pain is myalgic, etc.] The end result is improper evaluations leading to incorrect treatments and poor outcomes. The future is now. New methodology introduced by NeuroPAS can accurately determine the correct tissue pain generator [muscle, nerve, skeletal or joint]. This methodology also precisely identifies emotional or social factors that can affect subject’s symptoms and treatment outcomes. The test is called the Neurophysiologic Pain Profile or NP3. Expert Reviews. NP3 has been reviewed by scientists, physicians and experts from Johns Hopkins, University of Miami, UCLA, United Kingdom, and Argentina. Multiple companies including Neurodyne, ThoughtTechnology, and RS Medical have evaluated the methods. All have agreed that it is valid tool and a breakthrough in the assessment of pain symptomatology. Award winning. NP3 was entered into the international contest “Modern Marvels/Invent Now Challenge” sponsored by TIME Magazine, Invent Now, Inc. and History Channel. From over 4000 entries, NP3 was recognized as one of the top inventions for the year 2006. What can NP3 provide to patients, clinicians and society? By clearly separating and identifying the factors that dominant a subject’s particular pain symptoms, one can develop better interventions. Experience with hundreds of patients reveals that this accuracy reduces suffering, decreases disability, reduces unnecessary medications, prevents unnecessary surgeries, and avoids unnecessary nerve blocks. Conversely, it supports surgery and aggressive care when appropriate for better outcomes. It also identifies the physiological profiles of malingers and drug-seeking. Thus, NP3 can assist chronic pain suffers and clinicians to offer the proper treatment with better outcomes and improved utilization of all medical treatment avenues. It can also help identify malingering and drug-seeking individuals who would use the medical system for inappropriate personal reasons. |
|
Contact Us
You Can Reach NeuroPAS at:
NeuroPAS
1525 Killearn Center Blvd
Tallahassee FL, 32309
Phone: 850-893-6706
Email:info@neuropas.com